OMERS ADMINISTRATION Corp Buys Shares of 81,400 Personalis, Inc. (NASDAQ:PSNL)

OMERS ADMINISTRATION Corp acquired a new position in Personalis, Inc. (NASDAQ:PSNL) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 81,400 shares of the company’s stock, valued at approximately $470,000. OMERS ADMINISTRATION Corp owned approximately 0.12% of Personalis at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Lightspeed Management Company L.L.C. purchased a new stake in Personalis in the fourth quarter worth about $47,169,000. Blue Water Life Science Advisors LP increased its holdings in Personalis by 13.3% in the 4th quarter. Blue Water Life Science Advisors LP now owns 1,132,900 shares of the company’s stock worth $6,548,000 after acquiring an additional 132,900 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Personalis by 144.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 410,083 shares of the company’s stock worth $2,372,000 after acquiring an additional 242,141 shares during the period. Jane Street Group LLC lifted its holdings in Personalis by 144.3% during the fourth quarter. Jane Street Group LLC now owns 401,314 shares of the company’s stock valued at $2,320,000 after purchasing an additional 237,033 shares in the last quarter. Finally, abrdn plc bought a new position in shares of Personalis in the fourth quarter worth approximately $1,722,000. 61.91% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on PSNL shares. Craig Hallum initiated coverage on Personalis in a report on Monday, March 17th. They set a “buy” rating and a $8.00 price target on the stock. Needham & Company LLC reissued a “buy” rating and set a $7.00 target price on shares of Personalis in a research note on Thursday, April 10th. Guggenheim began coverage on shares of Personalis in a research report on Thursday. They set a “buy” rating and a $6.00 price objective on the stock. Finally, HC Wainwright upped their target price on shares of Personalis from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, May 7th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Personalis currently has a consensus rating of “Buy” and an average price target of $7.67.

Personalis Price Performance

Shares of PSNL stock opened at $4.95 on Monday. The company has a market cap of $437.21 million, a PE ratio of -2.95 and a beta of 1.83. Personalis, Inc. has a 1 year low of $1.14 and a 1 year high of $7.20. The stock’s 50 day simple moving average is $3.76 and its two-hundred day simple moving average is $4.45.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The company had revenue of $20.61 million during the quarter, compared to analyst estimates of $17.41 million. Equities research analysts expect that Personalis, Inc. will post -1.4 EPS for the current year.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.